<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073810</url>
  </required_header>
  <id_info>
    <org_study_id>A095007 (RIPPLE)</org_study_id>
    <nct_id>NCT04073810</nct_id>
  </id_info>
  <brief_title>Residual Inflammation and Plaque Progression Long-term Evaluation</brief_title>
  <acronym>RIPPLE</acronym>
  <official_title>Residual Inflammation and Plaque Progression Long-term Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammation drives atherosclerotic plaque rupture triggering most acute coronary syndromes.
      Despite advances in diagnosis and management of atherosclerosis, patients with myocardial
      infarction (MI) remain at increased risk of recurrent events. The RIPPLE study aims to
      examine the relationship between residual coronary inflammation detected by 68Ga-DOTATATE PET
      in patients treated for MI to long-term plaque progression measured by CT coronary
      angiography (CTCA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While vascular inflammation can be detected using 18F-FDG PET, this method lacks inflammatory
      cell specificity and is unreliable for coronary imaging because of high background signals
      from the myocardium. Upregulation of somatostatin receptor subtype-2 (SST2) occurs in
      activated macrophages, offering a novel inflammation imaging target. 68Ga-DOTATATE, an SST2
      PET tracer with low myocardial binding, shows promise for imaging coronary inflammation.
      Having previously demonstrated increased 68Ga-DOTATATE signals in coronary atherosclerotic
      lesions post-MI, we now aim to study the natural history of residual arterial inflammation in
      non-culprit arteries and better understand how 68Ga-DOTATATE signals relate to plaque
      morphology, progression and rupture.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>68Ga-DOTATATE PET vs. plaque progression</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of non-culprit coronary artery 68Ga-DOTATATE tissue-to-blood ratio at 12 weeks post-MI in patients with plaque progression (changes in low attenuation plaque volume and total atheroma volume) after 2 years measured by CTCA versus those without</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>68Ga-DOTATATE PET vs. CTCA-defined plaque morphology</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of coronary 68Ga-DOTATATE imaging to changes in plaque morphology measured by CTCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>68Ga-DOTATATE PET vs. intravascular imaging</measure>
    <time_frame>Baseline</time_frame>
    <description>Comparison of 68Ga-DOTATATE imaging to plaque morphology defined by high-resolution intravascular imaging performed during invasive coronary angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>68Ga-DOTATATE PET vs. hsCRP</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of 68Ga-DOTATATE PET to high-sensitivity C-reactive protein</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Myocardial infarction</arm_group_label>
    <description>Patients with recent MI</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET imaging</intervention_name>
    <description>Coronary 68Ga-DOTATATE PET-MRI or PET-CT at baseline and 3 months</description>
    <arm_group_label>Myocardial infarction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Coronary CT angiography</intervention_name>
    <description>CTCA at baseline and 2 years</description>
    <arm_group_label>Myocardial infarction</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with recent myocardial infarction and medically managed non-culprit coronary
        artery disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participants &gt;18 years old

          -  Able to give written, informed consent and to lie flat

          -  First-presentation of myocardial infarction within ~2 weeks

          -  At least mild non-culprit coronary artery disease on angiography, managed medically

        Exclusion Criteria:

          -  Women of child bearing potential not using adequate contraception

          -  Contrast allergy or contrast-nephropathy

          -  Uncontrolled atrial fibrillation

          -  Chronic kidney disease (eGFR &lt;30 mL/min/1.73 m2)

          -  Any medical condition, in the opinion of the investigator, that prevents the
             participant from lying flat during scanning, or from participating in the study

          -  Uncontrolled chronic inflammatory disorder

          -  History of recent malignancy deemed relevant to the study by the investigator

          -  Current use of systemic corticosteroids

          -  Previous coronary artery bypass grafting surgery (CABG) or percutaneous coronary
             intervention (PCI) before the index event

          -  Contraindication to coronary angiography

          -  Requires CABG or staged non-culprit artery PCI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason M Tarkin, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason M Tarkin, MBBS PhD</last_name>
    <phone>+44(0)1223331504</phone>
    <email>jt545@cam.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Cambridge</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Jason M Tarkin, MBBS PhD</last_name>
      <phone>+44(0)1223331504</phone>
      <email>jt545@cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>James HF Rudd, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Tarkin JM, Joshi FR, Evans NR, Chowdhury MM, Figg NL, Shah AV, Starks LT, Martin-Garrido A, Manavaki R, Yu E, Kuc RE, Grassi L, Kreuzhuber R, Kostadima MA, Frontini M, Kirkpatrick PJ, Coughlin PA, Gopalan D, Fryer TD, Buscombe JR, Groves AM, Ouwehand WH, Bennett MR, Warburton EA, Davenport AP, Rudd JH. Detection of Atherosclerotic Inflammation by (68)Ga-DOTATATE PET Compared to [(18)F]FDG PET Imaging. J Am Coll Cardiol. 2017 Apr 11;69(14):1774-1791. doi: 10.1016/j.jacc.2017.01.060.</citation>
    <PMID>28385306</PMID>
  </reference>
  <reference>
    <citation>Pedersen SF, Sandholt BV, Keller SH, Hansen AE, Clemmensen AE, Sillesen H, Højgaard L, Ripa RS, Kjær A. 64Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques: Studies in Patients Undergoing Endarterectomy. Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1696-703. doi: 10.1161/ATVBAHA.114.305067. Epub 2015 May 14.</citation>
    <PMID>25977567</PMID>
  </reference>
  <reference>
    <citation>Rominger A, Saam T, Vogl E, Ubleis C, la Fougère C, Förster S, Haug A, Cumming P, Reiser MF, Nikolaou K, Bartenstein P, Hacker M. In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med. 2010 Feb;51(2):193-7. doi: 10.2967/jnumed.109.070672. Epub 2010 Jan 15.</citation>
    <PMID>20080898</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cambridge</investigator_affiliation>
    <investigator_full_name>Jason Tarkin</investigator_full_name>
    <investigator_title>Wellcome Clinical Research Career Development Fellow &amp; Clinical Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

